Pfizer's PD-L1 ADC started clinical trials for the first time in China.

According to the Drug Clinical Trial Registration and Information Disclosure Platform, Pfizer has initiated a Phase I clinical trial for PF-08046054 targeting solid tumor patients in China. PF-08046054 is a PD-L1-targeted ADC acquired by Pfizer through the acquisition of Seagen. This Phase I clinical trial aims to evaluate PF-08046054 as a monotherapy for late-stage solid malignant tumor patients.